1. Scrip
  2. >>Focus On Asia

Daewoong's SGLT-2 Inhibitor Set For First Filing After Phase III

First Korean Contender In Class

 
• By Jung Won Shin

Korean pharma firm poised to file for domestic approval of SGLT-2 inhibitor enavogliflozin after positive top-line Phase III data, marking progress for the country's first drug in the already crowded class. But will it be competitive?

diabetes
Daewoong Speeds Up Novel Drug Development • Source: Alamy

Daewoong Pharmaceutical Company Ltd. has unveiled promising top-line Phase III results for enavogliflozin both as monotherapy and in combination with metformin for the treatment of type 2 diabetes, potentially moving the first sodium-glucose co-transporter 2 (SGLT-2) inhibitor to be developed by a Korean company closer to launch.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Focus On Asia

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By Jung Won Shin

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.

What Is Fuelling Cell And Gene Therapies In India?

 
• By Vibha Ravi

Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?

Compass’ Bispecific BTC Contender Meets Phase II/III Endpoint

 
• By Jung Won Shin

Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.